{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"ChemicalStructureName","name":"4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate tosylate"},{"type":"CodeName","name":"BAY 43-9006 tosylate"},{"type":"CodeName","name":"BAY 54-9085"},{"type":"USBrandName","name":"Nexavar"},{"type":"Synonym","name":"sorafenib"},{"type":"NSCNumber","name":"724772"},{"type":"CASRegistryName","name":"475207-59-1"}],"definition":{"html":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis.  Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","text":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis.  Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/sorafenibtosylate","text":"Sorafenib Tosylate"},"nciConceptId":"C2194","nciConceptName":"Sorafenib Tosylate","termId":299013,"name":"sorafenib tosylate","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sorafenib-tosylate"}],"links":null}